ROCK2 and chronic graft versus host disease: Belmudosudil, approved by the Food and Drug Administration in 2021 for chronic graft-versus-host-disease (cGVHD) treatment, is an inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) [27].